Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Insight Molecular Diagnostics Inc. (IMDX) vs Myriad Genetics, Inc. (MYGN)

Insight Molecular Diagnostics Inc. and Myriad Genetics, Inc. are both Diagnostics & Research companies. Myriad Genetics, Inc. is the larger, with a market value of $396.0M against $129.3M — 3.1× the size. Myriad Genetics, Inc. grew revenue faster over the last twelve months: −3.16% against −60.8%. Myriad Genetics, Inc. has the higher net margin (−14.0% vs −2,955.6%) and the lower return on invested capital (−19.9% vs 0.00%). Across the 17 metrics below, Myriad Genetics, Inc. leads on 11 and Insight Molecular Diagnostics Inc. on 6.

Valuation

Metric IMDX MYGN Diagnostics & Research median
P/E n/m n/m 33.95
P/S 86.26 0.49 4.87
P/B n/m 1.30 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m n/m 25.20
EV/Sales 75.74 0.57 5.66
Earnings yield (38.01%) (28.54%) (1.75%)
Free cash flow yield (21.52%) (3.59%) (0.13%)

Profitability

Metric IMDX MYGN Diagnostics & Research median
Gross margin 48.32% 68.83% 50.89%
Operating margin (3,011.86%) (12.22%) (8.57%)
Net margin (2,955.63%) (13.96%) (6.37%)
Free cash flow margin (1,856.23%) (1.76%) 0.00%
Return on equity 488.68% (32.54%) (2.92%)
Return on assets (123.46%) (17.11%) (6.71%)
Return on invested capital 0.00% (19.92%) 0.00%

Growth

Metric IMDX MYGN Diagnostics & Research median
Revenue growth (TTM) (60.77%) (3.16%) 7.69%
EPS growth (last fiscal year) 64.59% (180.14%) —
Revenue growth, 5-year CAGR 27.24% 3.61% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMDX MYGN Diagnostics & Research median
Debt to equity (0.04) 0.40 0.11
Current ratio 2.00 2.21 2.02
Net debt to EBITDA (0.67) 2.11 0.78

Dividend

Metric IMDX MYGN Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric IMDX MYGN Diagnostics & Research median
Market cap 129.26m 395.99m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack